The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†
Glen Lutchman(National Institute of Diabetes and Digestive and Kidney Diseases), Jay H. Hoofnagle(National Institutes of Health), Rohit Loomba(University of California San Diego), Apurva A. Modi(National Institute of Diabetes and Digestive and Kidney Diseases), Theo Heller(National Institutes of Health), Tiebing Liang(Indiana University Health), Brian B. Borg(National Institute of Diabetes and Digestive and Kidney Diseases), Ahalya Premkumar(National Institutes of Health), Marc G. Ghany(National Institute of Diabetes and Digestive and Kidney Diseases), Kittichai Promrat(National Institute of Diabetes and Digestive and Kidney Diseases), David E. Kleiner(National Institutes of Health)
Cited by 241
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
|Hepatology|2008|3k
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
|Journal of Hepatology|1999|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k